CN107445952B - A kind of method and application of extracting grandisine and coptisine - Google Patents
A kind of method and application of extracting grandisine and coptisine Download PDFInfo
- Publication number
- CN107445952B CN107445952B CN201710723225.3A CN201710723225A CN107445952B CN 107445952 B CN107445952 B CN 107445952B CN 201710723225 A CN201710723225 A CN 201710723225A CN 107445952 B CN107445952 B CN 107445952B
- Authority
- CN
- China
- Prior art keywords
- column
- coptisine
- mother liquor
- ethanol
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 20
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 229930194512 grandisine Natural products 0.000 title abstract description 20
- 238000000605 extraction Methods 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 239000012452 mother liquor Substances 0.000 claims description 37
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 claims description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 30
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 claims description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 21
- 238000011068 loading method Methods 0.000 claims description 20
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 19
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 19
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 241000037740 Coptis chinensis Species 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000287 crude extract Substances 0.000 claims description 11
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 11
- 238000004809 thin layer chromatography Methods 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 238000001179 sorption measurement Methods 0.000 claims description 10
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 9
- 239000004952 Polyamide Substances 0.000 claims description 9
- 239000004519 grease Substances 0.000 claims description 9
- 229920002647 polyamide Polymers 0.000 claims description 9
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 claims description 9
- 241000218202 Coptis Species 0.000 claims description 8
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 8
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 7
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 6
- 229940093265 berberine Drugs 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 claims description 5
- 229910001626 barium chloride Inorganic materials 0.000 claims description 5
- OJVABJMSSDUECT-UHFFFAOYSA-L berberin sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 OJVABJMSSDUECT-UHFFFAOYSA-L 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- 230000000704 physical effect Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 1
- UEAPAHNNFSZHMW-UHFFFAOYSA-N stepahnine Natural products COC1=CC=CC(C2=C34)=C1CC3N(C)CCC4=CC1=C2OCO1 UEAPAHNNFSZHMW-UHFFFAOYSA-N 0.000 claims 1
- UEAPAHNNFSZHMW-CQSZACIVSA-N stephanine Chemical compound CN([C@@H]1CC2=C(C3=C11)C=CC=C2OC)CCC1=CC1=C3OCO1 UEAPAHNNFSZHMW-CQSZACIVSA-N 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract description 15
- 229940022698 acetylcholinesterase Drugs 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 239000003960 organic solvent Substances 0.000 abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 3
- 206010039966 Senile dementia Diseases 0.000 abstract description 3
- 238000004440 column chromatography Methods 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 19
- 102100033639 Acetylcholinesterase Human genes 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- ZPINJJOPURFFNV-WJWAULOUSA-N Grandisin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2[C@H]([C@H](C)[C@H](O2)C=2C=C(OC)C(OC)=C(OC)C=2)C)=C1 ZPINJJOPURFFNV-WJWAULOUSA-N 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- ZPINJJOPURFFNV-UHFFFAOYSA-N grandisin Natural products COC1=C(OC)C(OC)=CC(C2C(C(C)C(O2)C=2C=C(OC)C(OC)=C(OC)C=2)C)=C1 ZPINJJOPURFFNV-UHFFFAOYSA-N 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 239000005909 Kieselgur Substances 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AGIQIKMGJVLKMA-NLRWUALESA-N (3ar,4as,5s,5ar,6ar)-5a-methyl-3-methylidene-5-(3-oxobutyl)-3a,4,4a,5,6,6a-hexahydrocyclopropa[f][1]benzofuran-2-one Chemical compound C1[C@@H]2C(=C)C(=O)O[C@@H]2C[C@]2(C)[C@@H](CCC(=O)C)[C@@H]21 AGIQIKMGJVLKMA-NLRWUALESA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- SZMVXHRECFRCKQ-UHFFFAOYSA-M 2-ethanethioyloxyethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=S)OCC[N+](C)(C)C SZMVXHRECFRCKQ-UHFFFAOYSA-M 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- FPJQGFLUORYYPE-UHFFFAOYSA-N epiberberine Chemical compound C1=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C2OCOC2=C1 FPJQGFLUORYYPE-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- -1 rhizine Natural products 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于中药提取技术领域,公开了一种提取格兰地新和黄连碱的方法和应用,本发明要解决的技术问题为黄连碱和格兰地新提取的新技术和新用途,采用此方法提取黄连碱和格兰地新避免了反复柱层析而大量使用有机溶剂和繁琐费时,本发明还提供了格兰地新和黄连碱在预防和治疗老年痴呆症方面的新用途,其主要作用机理在于对乙酰胆碱酯酶的作用。The invention belongs to the technical field of traditional Chinese medicine extraction, and discloses a method and application for extracting Coptisine and Coptisine. The method for extracting coptisine and grandisine avoids repeated column chromatography and uses a large amount of organic solvents and is cumbersome and time-consuming. The present invention also provides new uses of coptisine and coptisine in the prevention and treatment of senile dementia. The mechanism of action lies in the effect on acetylcholinesterase.
Description
技术领域technical field
本发明涉及医药生产技术领域,具体为一种提取格兰地新和黄连碱的方法和应用。The invention relates to the technical field of pharmaceutical production, in particular to a method and application for extracting grandisine and coptisine.
背景技术Background technique
黄连是中国传统中药材之一,有悠久的用药历史,黄连含有丰富的原小檗碱型异喹啉类生物碱,该类化合物具有抗肿瘤、抗菌,抗HIV、降糖降脂等多种生物活性,还有低毒低成本等特点。此外,前期的研究发现黄连中药根碱、黄连碱、表小檗碱等原小檗碱型生物碱含量丰富。因为此类生物碱同分异构体多,结构相似,分离纯化(除小檗碱和巴马亭)相对困难,一般在市场上仅作为植化对照品,黄连碱和格兰地新分离纯化多采用传统的系统分离方法,采用多种层析材料,不同溶剂体系,反复应用各种层析材料进行柱层析,这样导致有机溶剂的大量运用,导致分离周期长,有机溶剂用量大,不仅不利于环境保护,同时也费时费力成本高,这样导致黄连碱和格兰地新价格昂贵,市场上一般仅作为植物化学对照品或者科研用试剂,这样后期的药理活性研究及其应用受到限制。Coptis chinensis is one of the traditional Chinese medicinal materials and has a long history of medication. Coptis chinensis is rich in proberberine-type isoquinoline alkaloids, which have anti-tumor, anti-bacterial, anti-HIV, hypoglycemic and lipid-lowering properties, etc. Biological activity, low toxicity and low cost. In addition, previous studies have found that Coptis chinensis is rich in proberberine-type alkaloids such as rhizine, coptisine, and epiberberine. Because there are many isomers of these alkaloids and their structures are similar, it is relatively difficult to separate and purify (except berberine and palmatine), so they are generally only used as phytochemical reference substances in the market, and the separation and purification of coptisine and grandisin Most of the traditional system separation methods are used, using a variety of chromatographic materials, different solvent systems, and repeated application of various chromatographic materials for column chromatography, which leads to the use of a large number of organic solvents, resulting in long separation cycles and large amounts of organic solvents. Not only It is not conducive to environmental protection, but also time-consuming, laborious and costly, which leads to the high price of coptisine and grandisin, which are generally only used as phytochemical reference substances or reagents for scientific research in the market, so the later pharmacological activity research and its application are limited.
发明内容Contents of the invention
本发明要解决的技术问题是克服现有的缺陷,提供一种提取格兰地新和黄连碱的方法,提取效率高,工艺稳定,利用硫酸黄连碱的不溶于水和醇的性质,其他的生物碱溶解度相对较大,可以利用重结晶分离出黄连碱,利用聚酰胺的反向层析和氢键吸附作用,分离出黄连中的酚型生物碱,进一步柱层析就可以得到格兰地新,大大减少了有机溶剂的用量,可以大大降低格兰地新和黄连碱的价格,为人们减轻了负担,可以有效解决背景技术中的问题。The technical problem to be solved in the present invention is to overcome the existing defects and provide a method for extracting Grandisine and Coptisine, which has high extraction efficiency and stable process, utilizes the insoluble properties of Coptisine Sulfate in water and alcohol, and other The solubility of alkaloids is relatively large, and recrystallization can be used to separate coptisine, and the phenolic alkaloids in coptis can be separated by reverse chromatography and hydrogen bond adsorption of polyamide, and further column chromatography can be used to obtain grandiose The invention greatly reduces the consumption of organic solvents, can greatly reduce the prices of grandisine and coptisine, reduces the burden on people, and can effectively solve the problems in the background technology.
为实现上述目的,本发明提供如下技术方案:一种提取格兰地新和黄连碱的方法,包括如下步骤:In order to achieve the above object, the present invention provides the following technical solutions: a method for extracting grandisine and coptisine, comprising the steps of:
1)黄连或者黄连须根粉碎提取母液:首先取出一公斤的黄连使用药材粉碎机进行粉碎或者黄连须根剪断粉碎;加浓盐酸10-20ml沉淀小檗碱,硅藻土过滤,母液备用;1) Coptidis or Coptis fibrous roots are crushed to extract the mother liquor: First, take out 1 kg of Coptidis Rhizoma and use a medicinal material grinder to crush it or cut and crush Coptis rhizome fibrous roots; add 10-20ml of concentrated hydrochloric acid to precipitate berberine, filter with diatomaceous earth, and use the mother liquor for later use;
2)母液去除油脂;向母液中加入氨水调节pH值为11,过滤,往滤液中加入乙醚或者石油醚萃取,除去低级性的油脂;2) Remove grease from the mother liquor; add ammonia water to the mother liquor to adjust the pH value to 11, filter, add ether or petroleum ether to the filtrate for extraction, and remove low-grade grease;
3)结晶:利用黄连碱在乙醇中溶解度较大,含量相对较高,其硫酸盐不溶于水及乙醇的物理性质,黄连碱的硫酸盐在乙醇中溶解度为1:500,小檗碱室温下的硫酸盐在乙醇中溶解度为1:30,在上述的碱溶液中加入90%的硫酸,边搅拌边逐滴加入,直至有黄色沉淀产生,黄色沉淀用1L-2L的乙醇在50℃超声溶解,逐滴加5-10ml硫酸反复重结晶两到三次,得到80%以上硫酸黄连碱沉淀,HPLC检测纯度为85%以上,然后加入摩尔比为1:1氯化钡溶液回流半小时,过滤浓缩,甲醇丙酮重结晶,以此得到黄连碱盐酸盐的晶体400-800mg;3) Crystallization: Utilizing the high solubility of coptisine in ethanol and relatively high content, its sulfate is insoluble in water and physical properties of ethanol. The solubility of coptisine sulfate in ethanol is 1:500. The solubility of sulfate in ethanol is 1:30. Add 90% sulfuric acid to the above alkali solution and add it drop by drop while stirring until a yellow precipitate is produced. The yellow precipitate is dissolved with 1L-2L of ethanol at 50°C by ultrasonic , add 5-10ml of sulfuric acid dropwise and recrystallize repeatedly two to three times to obtain more than 80% of coptisine sulfate precipitates, the HPLC detection purity is more than 85%, then add barium chloride solution with a molar ratio of 1:1 to reflux for half an hour, filter and concentrate , recrystallized from methanol acetone to obtain 400-800 mg of crystals of coptisine hydrochloride;
4)浓缩:使用上述剩余母液,用5%-10%的氢氧化钠调节滤液的pH值为10-11,游离出酚性生物碱,再通过过滤器进行过滤,滤液用5%-10%稀盐酸调节到pH值为7,上大孔树脂D101,以每分钟0.5%-2.5%的柱体积速度进行上柱吸附,再用95%乙醇进行洗脱,以此浓缩得到粗浸膏,粗浸膏使用1mol/L氨水溶解,以此得到上柱液;4) Concentration: Use the above remaining mother liquor, adjust the pH value of the filtrate to 10-11 with 5%-10% sodium hydroxide, free out phenolic alkaloids, and then filter through a filter, the filtrate is 5%-10% Dilute hydrochloric acid to adjust the pH value to 7, put macroporous resin D101 on the column for adsorption at a column volume rate of 0.5%-2.5% per minute, and then elute with 95% ethanol, and concentrate to obtain a crude extract. The extract is dissolved with 1mol/L ammonia water to obtain the upper column solution;
5)上柱:上柱时,按照柱体积的0.5%~1.0%/min上聚酰胺柱,然后,再使用0.8 -1.5mol/L的氨水洗脱;5) Column loading: When loading the column, apply the polyamide column at 0.5% to 1.0% of the column volume/min, and then use 0.8-1.5mol/L ammonia water to elute;
6)洗脱收集:按照柱体积的0.5%~1.0%/min上柱洗脱,当组分下移到柱子底部四分之三时,从上到下依次呈现A、B、C三个色带,收集B色带,然后用甲苯、乙酸乙酯、醋酸和甲醇按照体积比为4:2:1:1的展开剂和1份氨水双槽展开进行薄层鉴定,B色带组分为药根碱、非洲防己碱、格兰地新的混合物,用薄层层析检验流份,合并相同流份;6) Elution collection: The column is eluted according to 0.5% to 1.0% of the column volume/min. When the component moves down to the bottom three-quarters of the column, the three colors of A, B, and C appear sequentially from top to bottom Band, collect B color band, and then use toluene, ethyl acetate, acetic acid and methanol according to the volume ratio of 4:2:1:1 developer and 1 part of ammonia double tank development for TLC identification, B color band components are The mixture of jatrorrhizine, tetrandrine, and grandisin was tested by thin-layer chromatography, and the same fractions were combined;
7)制取格兰地新:调节B色带组组分的pH为7,上大孔树脂D101,以每分钟0.5%-2.5%的柱体积速度进行上柱吸附,水洗脱去无机盐,再使用95%乙醇洗脱,浓缩得到粗浸膏,丙酮和甲醇重结晶得到药根碱,母液为药根碱和非洲防己碱、格兰地新的混合物,母液并用100-200目硅胶拌样,300-400目硅胶柱层析,用氯仿和甲醇按照体积比为10:1到20:1的比例洗脱,再用甲苯、乙酸乙酯、醋酸和甲醇按照体积比为4:2:1:1的展开剂和1份氨水双槽展开,进行薄层鉴定,合并相同Rf值得到格兰地新,HPLC检测纯度为95%;7) Preparation of Grandysin: adjust the pH of the components of the B ribbon group to 7, put on the macroporous resin D101, carry out the adsorption on the column at a column volume rate of 0.5%-2.5% per minute, and wash off the inorganic salt with water , and then eluted with 95% ethanol, concentrated to obtain a crude extract, recrystallized from acetone and methanol to obtain jatrorrhizine, the mother liquor is a mixture of jatrorrhizine, African tetrandrine, and grandisin, and the mother liquor is mixed with 100-200 mesh silica gel Sample, 300-400 mesh silica gel column chromatography, eluted with chloroform and methanol according to the volume ratio of 10:1 to 20:1, and then with toluene, ethyl acetate, acetic acid and methanol according to the volume ratio of 4:2: 1:1 developer and 1 part of ammonia were developed in double tanks, and TLC identification was carried out, and the same Rf value was combined to obtain Grandicin, with a purity of 95% by HPLC;
作为本发明的一种优选技术方案,上述步骤2)中剩余母液在将pH值调至到10到11之后,需将溶液放置6-12小时。As a preferred technical solution of the present invention, after the pH value of the remaining mother liquor in step 2) is adjusted to 10 to 11, the solution needs to be left for 6-12 hours.
作为本发明的一种优选技术方案,上述步骤5)中上柱时,上柱溶液量为柱子体积的三分之一到四分之一时停止上柱。As a preferred technical solution of the present invention, when loading the column in the above step 5), stop loading the column when the volume of the column loading solution is 1/3 to 1/4 of the volume of the column.
作为本发明的一种优选技术方案,上述步骤5)和6)中,上柱时,按照柱体积的0.5%~1.0%/min上聚酰胺柱,然后,再使用0.8 -1.5mol/L的氨水洗脱;As a preferred technical solution of the present invention, in the above steps 5) and 6), when the column is loaded, the polyamide column is loaded according to 0.5% to 1.0%/min of the column volume, and then 0.8-1.5mol/L of Ammonia elution;
与现有技术相比,本发明的有益效果是:本提取格兰地新和黄连碱的方法和工艺,流程简单易行,提取效率,重复性好,对黄连碱和格兰地新对乙酰胆碱脂酶抑制活性未见文献报道,通过对黄连碱和格兰地新进行的活性筛选,发现具有具有较好乙酰胆碱脂酶的抑制活性,可以降低格兰地新和黄连碱的价格,为后续的研究提供物质基础。Compared with the prior art, the beneficial effects of the present invention are: the method and process for extracting Grandisine and Coptisine, the process is simple and easy, the extraction efficiency is good, and the repeatability is good. The lipase inhibitory activity has not been reported in the literature. Through the activity screening of Coptisine and Coptisine, it is found that it has a good inhibitory activity of acetylcholinesterase, which can reduce the price of Coptisine and Coptisine, and provide the follow-up Research provides the material basis.
具体实施方式Detailed ways
下面将结合本发明实施事例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the implementation examples of the present invention. Obviously, the described embodiments are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.
实施例一:Embodiment one:
一种提取格兰地新和黄连碱的方法,包括如下步骤:A method for extracting grandisine and coptisine, comprising the steps of:
1)黄连粉碎提取母液:首先取出一公斤的黄连或者黄连须使用药材粉碎机进行粉碎,加浓盐酸10ml沉淀小檗碱,硅藻土过滤,母液备用;1) Coptis chinensis is crushed to extract the mother liquor: first take out 1 kg of Coptis chinensis or Coptis chinensis must be crushed with a medicinal material grinder, add 10ml of concentrated hydrochloric acid to precipitate berberine, filter with diatomaceous earth, and use the mother liquor for later use;
2)去除油脂;向母液中加入氨水调节pH值为11,再加入乙醚或者石油醚萃取,除去低级性的油脂;2) Remove grease; add ammonia water to the mother liquor to adjust the pH value to 11, then add ether or petroleum ether for extraction to remove low-grade grease;
3)结晶:在剩余的碱溶液中加入90%的硫酸,边搅拌边逐滴加入,直至有黄色沉淀产生,黄色沉淀用2L的乙醇进行在50℃超声溶解,逐滴加2-3ml反复重结晶两到三次,得到80%以上硫酸黄连碱沉淀,HPLC检测纯度为85%以上,再用甲醇或者乙醇溶解,然后加入摩尔比为1:1氯化钡溶液回流半小时,再通过过滤器进行过滤,甲醇丙酮重结晶,以此得到黄连碱盐酸盐的晶体400mg;3) Crystallization: add 90% sulfuric acid to the remaining alkaline solution, add dropwise while stirring until a yellow precipitate is produced, and use 2L of ethanol to dissolve the yellow precipitate ultrasonically at 50°C, add 2-3ml dropwise and repeat repeatedly Crystallize two to three times to obtain more than 80% of berberine sulfate precipitates, and the HPLC detection purity is more than 85%, then dissolve with methanol or ethanol, then add barium chloride solution with a molar ratio of 1:1 and reflux for half an hour, and then pass through the filter. Filter and recrystallize from methanol acetone to obtain 400 mg of crystals of coptisine hydrochloride;
4)浓缩:使用剩余母液用5%氢氧化钠游离出酚性生物碱,再用5%的氢氧化钠调节滤液的pH值为10,剩余母液在将pH值调至到10之后,游离出酚性生物碱,需将溶液放置6小时,再通过过滤器进行过滤,滤液用5%稀盐酸调节到pH值为7,上大孔树脂D101,以每分钟0.5%的柱体积速度进行上柱吸附,再用95%乙醇进行洗脱,以此浓缩得到粗浸膏,粗浸膏使用1mol/L氨水溶解,以此得到上柱液;4) Concentration: Use the remaining mother liquor to free phenolic alkaloids with 5% sodium hydroxide, then adjust the pH value of the filtrate to 10 with 5% sodium hydroxide, and then free the remaining mother liquor after adjusting the pH value to 10. For phenolic alkaloids, the solution needs to be left for 6 hours, and then filtered through a filter. The filtrate is adjusted to a pH value of 7 with 5% dilute hydrochloric acid, and the macroporous resin D101 is loaded on the column at a column volume rate of 0.5% per minute. Adsorbed, and then eluted with 95% ethanol, concentrated to obtain a crude extract, which was dissolved with 1mol/L ammonia water to obtain the upper column liquid;
5)上柱:上柱时,按照柱体积的0.5%/min上聚酰胺柱,且上柱溶液量为柱子体积的三分之一时停止上柱,然后,再使用0.8mol/L的氨水洗脱;5) Column loading: When loading the column, load the polyamide column at 0.5%/min of the column volume, and stop loading the column when the volume of the column solution is one-third of the column volume, and then use 0.8mol/L ammonia water Elution;
6)洗脱收集:按照柱体积的0.5%/min上柱洗脱,当组分下移到柱子底部时四分之三时,从上到下依次呈现A、B、C三个色带,收集B色带,然后用甲苯、乙酸乙酯、醋酸和甲醇按照体积比为4:2:1:1的展开剂和1份氨水双槽展开进行薄层鉴定,B色带组分为药根碱、非洲防己碱、格兰地新的混合物,用薄层层析检验流份,合并相同流份;6) Elution collection: The column is eluted at 0.5%/min of the column volume. When the component moves down to three quarters of the bottom of the column, three color bands of A, B, and C appear in sequence from top to bottom. Collect B color band, and then use toluene, ethyl acetate, acetic acid and methanol according to the volume ratio of 4:2:1:1 developer and 1 part of ammonia double tank development for TLC identification, the B color band component is the root The mixture of alkali, tetrandrine, and grandisin, the fractions were tested by thin-layer chromatography, and the same fractions were combined;
7)制取格兰地新:调节B色带组组分的pH值为7,上大孔树脂D101,以每分钟0.5%的柱体积速度进行上柱吸附,再使用95%乙醇洗脱,浓缩得到粗浸膏,丙酮和甲醇重结晶得到药根碱,母液为药根碱和非洲防己碱、格兰地新的混合物,母液用100目硅胶拌样,300目硅胶柱层析,用氯仿和甲醇按照体积比为20:1的比例洗脱,甲苯、乙酸乙酯、醋酸和甲醇按照体积比为4:2:1:1的展开剂和1份氨水双槽展开进行薄层鉴定,合并相同Rf值得到格兰地新300mg,HPLC检测纯度为95%。7) Preparation of Grandysin: adjust the pH value of the components of the B ribbon group to 7, apply the macroporous resin D101 to the column for adsorption at a column volume rate of 0.5% per minute, and then use 95% ethanol to elute. Concentrate to obtain crude extract, recrystallize from acetone and methanol to obtain jatrorrhizine, the mother liquor is a mixture of jatrorrhizine, tetrandrine and grandisine, the mother liquor is mixed with 100 mesh silica gel, 300 mesh silica gel column chromatography, and chloroform and methanol were eluted at a volume ratio of 20:1, and toluene, ethyl acetate, acetic acid, and methanol were developed with a volume ratio of 4:2:1:1 as a developing solvent and 1 part of ammonia water for TLC identification, and combined With the same Rf value, 300 mg of Grandisine was obtained, and the purity by HPLC was 95%.
实施例二:Embodiment two:
一种提取格兰地新和黄连碱的方法,包括如下步骤:A method for extracting grandisine and coptisine, comprising the steps of:
1)黄连粉碎提取母液:首先取出一公斤的黄连或者黄连须使用药材粉碎机进行粉碎,加浓盐酸15ml沉淀小檗碱,硅藻土过滤,母液备用;1) Coptis chinensis is crushed to extract the mother liquor: first take out 1 kg of Coptis chinensis or Coptis chinensis must be crushed with a medicinal material grinder, add 15ml of concentrated hydrochloric acid to precipitate berberine, filter with diatomaceous earth, and use the mother liquor for later use;
2)去除油脂;向母液中加入氨水调节pH值为11,再加入乙醚或者石油醚萃取,除去低级性的油脂;2) Remove grease; add ammonia water to the mother liquor to adjust the pH value to 11, then add ether or petroleum ether for extraction to remove low-grade grease;
3)结晶:在剩余的碱溶液中加入90%的硫酸,边搅拌边逐滴加入,直至有黄色沉淀产生,黄色沉淀用1L的乙醇在50℃进行超声部分溶解,逐滴加10ml硫酸反复重结晶两到三次,得到80%以上硫酸黄连碱沉淀,HPLC检测纯度为85%以上,再用甲醇或者乙醇溶解,然后加入摩尔比为1:1氯化钡溶液回流半小时,再通过过滤器进行过滤,甲醇丙酮重结晶,以此得到黄连碱盐酸盐的晶体500mg;3) Crystallization: Add 90% sulfuric acid to the remaining alkali solution, add dropwise while stirring until a yellow precipitate is produced, and use 1L of ethanol to ultrasonically dissolve the yellow precipitate at 50°C, add 10ml sulfuric acid dropwise and repeat Crystallize two to three times to obtain more than 80% of berberine sulfate precipitates, and the HPLC detection purity is more than 85%, then dissolve with methanol or ethanol, then add barium chloride solution with a molar ratio of 1:1 and reflux for half an hour, and then pass through the filter. Filter and recrystallize from methanol acetone to obtain 500 mg of crystals of coptisine hydrochloride;
4)浓缩:使用上述剩余母液,用8%的氢氧化钠调节滤液的pH值为11,剩余母液在将pH值调至到10之后,游离出酚性生物碱,需将溶液放置8小时,再通过过滤器进行过滤,滤液用6%稀盐酸调节到pH值为7,上大孔树脂D101,以每分钟1%的柱体积速度进行上柱吸附,再用95%乙醇进行洗脱,以此浓缩得到粗浸膏,粗浸膏使用1mol/L氨水溶解,以此得到上柱液;4) Concentration: use the remaining mother liquor above, adjust the pH value of the filtrate to 11 with 8% sodium hydroxide, and release the phenolic alkaloid after the pH value of the remaining mother liquor is adjusted to 10. The solution needs to be placed for 8 hours. Filter through a filter again, the filtrate is adjusted to a pH value of 7 with 6% dilute hydrochloric acid, and the macroporous resin D101 is applied to the column for adsorption at a column volume rate of 1% per minute, and then eluted with 95% ethanol to This concentration obtains a crude extract, which is dissolved with 1mol/L ammonia water to obtain the upper column liquid;
5)上柱:上柱时,按照柱体积的0.7%/min上聚酰胺柱,上柱溶液量为柱子体积的三分之一时停止上柱,然后,再使用1.0mol/L的氨水洗脱;5) Column loading: When loading the column, load the polyamide column at 0.7%/min of the column volume, stop loading the column when the volume of the column loading solution is one-third of the column volume, and then wash with 1.0mol/L ammonia water off;
6)洗脱收集:按照柱体积的0.7%/min上柱洗脱,当组分下移到柱子底部时四分之三时,从上到下依次呈现A、B、C三个色带,收集B色带,然后用甲苯、乙酸乙酯、异丙醇、甲醇、氨水体积比为6:3:1.5:2:0.5的展开剂进行薄层鉴定,B色带组分为药根碱、非洲防己碱、格兰地新的混合物,用薄层层析检验流份,合并相同流份;6) Elution collection: The column is eluted at 0.7%/min of the column volume. When the component moves down to three quarters of the bottom of the column, three color bands of A, B, and C appear in sequence from top to bottom. Collect the color band B, and then carry out thin-layer identification with a developer with a volume ratio of toluene, ethyl acetate, isopropanol, methanol, and ammonia water at a volume ratio of 6:3:1.5:2:0.5. The components of the color band B are jatrorrhizine, The mixture of tetrandrine and grandiose new, use thin layer chromatography to test the fractions, and combine the same fractions;
7)制取格兰地新:调节B色带组组分的pH值为7,上大孔树脂D101,以每分钟1%的柱体积速度进行上柱吸附,再使用95%乙醇洗脱,浓缩得到粗浸膏,丙酮和甲醇重结晶得到药根碱,母液为药根碱和非洲防己碱、格兰地新的混合物,母液用100目硅胶拌样,300-400目硅胶柱层析,用氯仿和甲醇按照体积比为10:1的比例洗脱,再用甲苯、乙酸乙酯、醋酸和甲醇按照体积比为4:2:1:1的展开剂进行薄层鉴定,合并相同Rf值得到格兰地新50mg,HPLC检测纯度为95%。7) Preparation of Grandysin: adjust the pH value of the components of the B ribbon group to 7, apply the macroporous resin D101 to the column for adsorption at a column volume rate of 1% per minute, and then use 95% ethanol to elute. Concentrate to obtain a crude extract, recrystallize from acetone and methanol to obtain jatrorrhizine, the mother liquor is a mixture of jatrorrhizine, tetrandrine and grandisine, the mother liquor is mixed with 100 mesh silica gel, and 300-400 mesh silica gel column chromatography, Elute with chloroform and methanol at a volume ratio of 10:1, then use toluene, ethyl acetate, acetic acid, and methanol for TLC identification at a volume ratio of 4:2:1:1, and combine the same Rf values To the new 50mg of grandiose, the HPLC detection purity is 95%.
实施例三:Embodiment three:
一种提取格兰地新和黄连碱的方法,包括如下步骤:A method for extracting grandisine and coptisine, comprising the steps of:
1)黄连须根剪断提取母液:首先取出一公斤的黄连或者黄连须使用药材粉碎机进行粉碎,加浓盐酸10-20ml沉淀小檗碱,硅藻土过滤,母液备用;1) Coptis fibrous roots are cut to extract the mother liquor: first take out 1 kg of Coptis rhizome or Coptis chinensis and grind it with a medicinal material grinder, add 10-20ml of concentrated hydrochloric acid to precipitate berberine, filter with diatomaceous earth, and use the mother liquor for later use;
2)去除油脂;向母液中加入氨水调节pH值为11,再加入乙醚或者石油醚萃取,除去低级性的油脂;2) Remove grease; add ammonia water to the mother liquor to adjust the pH value to 11, then add ether or petroleum ether for extraction to remove low-grade grease;
3)结晶:在剩余的碱溶液中加入90%的硫酸,边搅拌边逐滴加入,直至有黄色沉淀产生,黄色沉淀用1L乙醇在50℃超声溶解,逐滴加6ml浓硫酸反复重结晶两到三次,逐滴加入,边加边搅拌,得到80%以上硫酸黄连碱沉淀,HPLC检测纯度为85%以上,再用200ml甲醇或者乙醇,然后加入约摩尔比为1:1(硫酸黄连碱:氯化钡)回流半小时,再通过过滤器进行过滤,甲醇丙酮重结晶,以此得到黄连碱盐酸盐的晶体600mg;3) Crystallization: Add 90% sulfuric acid to the remaining alkaline solution, and add dropwise while stirring until a yellow precipitate is produced. The yellow precipitate is dissolved with 1L ethanol at 50°C by ultrasound, and 6ml of concentrated sulfuric acid is added dropwise to recrystallize repeatedly. To three times, add dropwise, stir while adding, obtain more than 80% berberine sulfate precipitation, HPLC detection purity is more than 85%, then use 200ml methanol or ethanol, then add about molar ratio and be 1:1 (berberine sulfate: Barium chloride) was refluxed for half an hour, then filtered through a filter, and recrystallized from methanol and acetone to obtain 600 mg of crystals of coptisine hydrochloride;
4)浓缩:使用上述剩余母液,用10%的氢氧化钠调节滤液的pH值为11,剩余母液在将pH值调至到10之后,游离出酚性生物碱,需将溶液放置10小时,再通过过滤器进行过滤,滤液用8%稀盐酸调节到pH值为7,上大孔树脂D101,以每分钟2.0%的柱体积速度进行上柱吸附,再用95%乙醇进行洗脱,以此浓缩得到粗浸膏,粗浸膏使用1mol/L氨水溶解,以此得到上柱液;4) Concentration: use the above remaining mother liquor, adjust the pH value of the filtrate to 11 with 10% sodium hydroxide, and release the phenolic alkaloid after the pH value of the remaining mother liquor is adjusted to 10. The solution needs to be placed for 10 hours. Filter through a filter again, the filtrate is adjusted to a pH value of 7 with 8% dilute hydrochloric acid, and the macroporous resin D101 is applied to the column for adsorption at a column volume rate of 2.0% per minute, and then eluted with 95% ethanol to This concentration obtains a crude extract, which is dissolved with 1mol/L ammonia water to obtain the upper column liquid;
5)上柱:上柱时,按照柱体积的0.8%/min上聚酰胺柱,上柱溶液量为柱子体积的三分之一时停止上柱,然后,再使用1.3mol/L的氨水洗脱;5) Column loading: When loading the column, load the polyamide column at 0.8%/min of the column volume, stop loading the column when the volume of the column loading solution is one-third of the column volume, and then wash with 1.3mol/L ammonia water off;
6)洗脱收集:按照柱体积的0.8%/min上柱洗脱,当组分下移到柱子底部时四分之三时,从上到下依次呈现A、B、C三个色带,收集B色带,然后用甲苯、乙酸乙酯、醋酸和甲醇按照体积比为4:2:1:1的展开剂和1份氨水进行薄层鉴定,B色带组分为药根碱、非洲防己碱、格兰地新的混合物,用薄层层析检验流份,合并相同流份;6) Elution collection: The column is eluted at 0.8%/min of the column volume. When the component moves down to three quarters of the bottom of the column, three color bands of A, B, and C appear sequentially from top to bottom. Collect B color band, and then use toluene, ethyl acetate, acetic acid and methanol according to the volume ratio of 4:2:1:1 developer and 1 part of ammonia for TLC identification. The components of B color band are jatrorrhizine, African For the mixture of tetrandrine and grandisine, the fractions were tested by thin layer chromatography, and the same fractions were combined;
7)制取格兰地新:调节B色带组组分的pH值为7,上大孔树脂D101,以每分钟2.0%的柱体积速度进行上柱吸附,再使用95%乙醇洗脱,浓缩得到粗浸膏,丙酮和甲醇重结晶得到药根碱,母液为药根碱和非洲防己碱、格兰地新的混合物,母液用60-100目硅胶拌样,300-400目硅胶柱层析,用氯仿和甲醇按照体积比为20:1的比例洗脱,再用甲苯、乙酸乙酯、醋酸和甲醇按照体积比为4:2:1:1的展开剂和1份氨水进行薄层鉴定,合并相同Rf值得到格兰地新40mg,HPLC检测纯度为95%。7) Preparation of Grandysin: adjust the pH value of the components of the B ribbon group to 7, apply the macroporous resin D101 to the column for adsorption at a column volume rate of 2.0% per minute, and then use 95% ethanol to elute. Concentrate to obtain crude extract, recrystallize with acetone and methanol to obtain jatrorrhizine, the mother liquor is a mixture of jatrorrhizine, African tetrandrine, and grandisin, the mother liquor is mixed with 60-100 mesh silica gel, and 300-400 mesh silica gel column layer analysis, eluted with chloroform and methanol according to the volume ratio of 20:1, and then used toluene, ethyl acetate, acetic acid and methanol according to the volume ratio of 4:2:1:1 developer and 1 part of ammonia for thin layer Identification, combined with the same Rf value to obtain Grandicin 40mg, the HPLC detection purity was 95%.
实施例四、格兰地新和黄连碱对乙酰胆碱脂酶抑制活性Embodiment four, grandisine and coptisine inhibit activity of acetylcholinesterase
原理:乙酰胆碱脂酶与碘化硫代乙酰胆碱生成的产物,与5,5-二硫双硝基苯甲酸生成一种黄色物质,可以利用该颜色反应,来测定待测样品对乙酰胆碱脂酶的抑制程度。具体方法见文献:孙黔云 杨付梅. 乙酰胆碱酯酶抑制剂微量筛选模型的比较研究《中国药理学通报》2008, 24(10):1387-1392 5.采用Ellman 法 对 AChE 体外抑制活性进行测试,用碘化乙酰胆碱为底物,化学标记的二硫硝基苯甲酸为显 色 剂, 在96 孔 板 上 对 样 品的AChE 抑制活性进行测定。选用他克林为阳性对照药。得到对乙酰胆碱脂酶三个不同浓度的抑制率。Principle: The product of acetylcholinesterase and thioacetylcholine iodide generates a yellow substance with 5,5-dithiobisnitrobenzoic acid. This color reaction can be used to determine the inhibition of the test sample on acetylcholinesterase degree. For specific methods, please refer to the literature: Sun Qianyun, Yang Fumei. Comparative Study on Micro-screening Models of Acetylcholinesterase Inhibitors "Chinese Pharmacology Bulletin" 2008, 24(10): 1387-1392 5. Ellman method was used to test the inhibitory activity of AChE in vitro. Acetylcholine was used as the substrate, and chemically labeled dithionitrobenzoic acid was used as the chromogen, and the AChE inhibitory activity of the samples was determined on a 96-well plate. Tacrine was selected as the positive control drug. The inhibition rate of three different concentrations of acetylcholinesterase was obtained.
见表一See Table 1
表一黄连碱和格兰地新对 乙酰胆碱脂酶和丁酰胆碱脂酶的单浓度抑制率Table 1 The single-concentration inhibitory rate of coptisine and grandisine to acetylcholinesterase and butyrylcholinesterase
从表一简单比较,格兰地新和黄连碱具有明显的抑制乙酰胆酯酶的作用,特别是格兰地新在单浓度1×10-6 mol/L-1,对乙酰胆碱脂酶的抑制率超过50%,说明对两种酶抑制活性有较好的选择性,可能成为治疗老年痴呆的药物,其作用机理主要是对乙酰胆碱脂酶的抑制。From the simple comparison in Table 1, Grandiseine and coptisine have obvious inhibitory effect on acetylcholinesterase, especially the inhibitory effect of Grandiseine on acetylcholinesterase at a single concentration of 1×10 -6 mol/L -1 The rate exceeds 50%, indicating that it has good selectivity for the two enzyme inhibitory activities, and may become a drug for the treatment of senile dementia, and its mechanism of action is mainly the inhibition of acetylcholinesterase.
本发明流程简单易行,重复性好,提取效率高,可以大大降低含有格兰地新和黄连碱价格,为后续研究提供物质基础,增加黄连的附加值。对黄连碱和格兰地新对乙酰胆碱脂酶抑制活性未见文献报道,通过对黄连碱和格兰地新进行的活性筛选,发现具有乙酰胆碱脂酶的抑制活性,本发明揭示了格兰地新和黄连碱具有对乙酰胆碱酯酶的抑制作用,具有开发成抗老年痴呆药物的应用前景。The process of the invention is simple and easy, the repeatability is good, and the extraction efficiency is high, the price of the alkaloids containing grandisine and coptis can be greatly reduced, a material basis is provided for follow-up research, and the added value of the coptis is increased. There is no literature report on the inhibitory activity of coptisine and grandisine on acetylcholinesterase. Through the activity screening of coptisine and grandisine, it is found that it has the inhibitory activity of acetylcholinesterase. The present invention discloses that grandisine Coptisine has the inhibitory effect on acetylcholinesterase, and has the application prospect of being developed as an anti-senile dementia drug.
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。Although the embodiments of the present invention have been shown and described, those skilled in the art can understand that various changes, modifications and substitutions can be made to these embodiments without departing from the principle and spirit of the present invention. and modifications, the scope of the invention is defined by the appended claims and their equivalents.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710723225.3A CN107445952B (en) | 2017-08-22 | 2017-08-22 | A kind of method and application of extracting grandisine and coptisine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710723225.3A CN107445952B (en) | 2017-08-22 | 2017-08-22 | A kind of method and application of extracting grandisine and coptisine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107445952A CN107445952A (en) | 2017-12-08 |
CN107445952B true CN107445952B (en) | 2019-12-24 |
Family
ID=60492989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710723225.3A Expired - Fee Related CN107445952B (en) | 2017-08-22 | 2017-08-22 | A kind of method and application of extracting grandisine and coptisine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107445952B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109575010B (en) * | 2018-12-29 | 2021-07-20 | 西南大学 | Method for extracting methylberberine from mother liquor of Coptis chinensis, high-purity methylberberine prepared therefrom and application |
CN110179859B (en) * | 2019-06-27 | 2021-09-24 | 香港科技大学深圳研究院 | Application of Fangji Extract and Fangji Norline Base in Pharmaceutical |
CN111704609B (en) * | 2020-07-03 | 2021-04-06 | 重庆睿宝生物科技有限公司 | Method for refining berberine hydrochloride by barium chloride |
CN118191130B (en) * | 2024-03-06 | 2024-11-19 | 南方医科大学第五附属医院 | One-test-multiple-evaluation method for determining content of 7 alkaloid components in coptis chinensis detoxification soup |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104418852B (en) * | 2013-08-30 | 2016-08-17 | 西南大学 | A kind of high-purity coptisine extracting method and application |
-
2017
- 2017-08-22 CN CN201710723225.3A patent/CN107445952B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN107445952A (en) | 2017-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107445952B (en) | A kind of method and application of extracting grandisine and coptisine | |
CN101891750B (en) | Preparation method of stephanine and hydrochloride thereof | |
CN102399187B (en) | Preparation method of sinomenine | |
CN101928285A (en) | A method for extracting main alkaloids in Coptidis rhizome | |
CN106892949B (en) | A method of extracting separation glycyrrhizic acid, glycyrrhiza total flavonoid simultaneously based on continuous chromatography technology | |
CN106967142B (en) | A kind of method for extracting Mogroside V, VI and 11-O base V simultaneously | |
CN101003554A (en) | Method for preparing tetrahydroxy diphenyl ethylene glycoside separated from fleece-flower root | |
CN115703740B (en) | Preparation method of bulleyaconitine A | |
CN102408415B (en) | Preparation method of mangiferin | |
CN101974007B (en) | Method for extracting bergenin from traditional Chinese medicine rodgersia podophylla | |
CN104402950B (en) | A kind of picroside Ⅰ crystallization preparation method | |
CN1172933C (en) | Prepn of matrine, oxymatrine and sophoxidine from flavescent sophora root | |
WO2012061984A1 (en) | Method for preparing albiflorin and paeoniflorin | |
CN101168537A (en) | Method for preparing andrographolide and dehydroandrographolide simultaneously | |
CN102600113A (en) | Organic solvent-free preparation method of sinomenine hydrochloride cataplasm | |
CN102397267B (en) | Method for preparing sinomenine hydrochloride cataplasma | |
CN103588831A (en) | Preparation method of glycyrrhizic acid | |
CN102603632A (en) | Method for preparing sinomenine hydrochloride by using non-organic solvent | |
CN104418852B (en) | A kind of high-purity coptisine extracting method and application | |
CN101967505A (en) | Method for preparing dihydro quercetin | |
CN104693249A (en) | Method for simultaneously separating and preparing syringin and oleuropein from syringa oblate lindl. | |
CN104402949B (en) | A kind of method that separation simultaneously prepares Syringin and oleuropein from lilac | |
CN101328198A (en) | Extraction and separation method of syringin | |
CN105601693A (en) | Preparation of Ginsenoside F1 and Its Antitumor Effect | |
CN106939006B (en) | A method of separation hydrastine being extracted in northern corydalis from matching |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191224 |
|
CF01 | Termination of patent right due to non-payment of annual fee |